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spect to the AUC of change to baseline in infiltrate thickness 
was demonstrated. Both medications were well tolerated. 
Overall, Mometasone cream and the mometasone compara-
tor showed similar efficacy and tolerability. Mometasone 
cream, in addition to its high potency and good tolerability, 
provides the properties of a light cream, which might make 
this new medication particularly suitable for application on 
acutely inflamed and sensitive skin. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Establishing topical glucocorticoid therapy has been 
one of the most significant advances in dermatology  [1] . 
For five decades these agents have been used in the treat-
ment of skin diseases due to their undebatable potency in 
reducing inflammation  [1–3] . Besides their anti-inflam-
matory potency, corticosteroids show a wide-ranging 
spectrum of actions including antimitotic activity  [4] and 
immunosuppressive effects, which are at least partly at-
tributable to the inhibition of the release of various cyto-
kines  [3] . Since the introduction of hydrocortisone for 
topical use, more potent glucocorticoid congeners have 
been developed.
 The long-term use of topical glucocorticoids is still 
limited by both topical and systemic side effects with skin 
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 Abstract 
 Mometasone furoate, a potent glucocorticoid (class III) with 
a favorable benefit/risk ratio, has emerged as a standard 
medication for the treatment of inflammatory skin disorders. 
The purpose of the investigation presented here was to de-
termine the noninferiority of a topical mometasone formula-
tion, a light cream (O/W 60/40 emulsion) with mometasone 
furoate 0.1% (water content of 33%) versus marketed com-
parators. Using the vasoconstrictor assay, a strong blanching 
effect of the new cream (called Mometasone cream) compa-
rable to that of a mometasone comparator, a fatty cream 
with mometasone furoate 0.1%, could be demonstrated. 
Thus, the topical bioavailability of the active ingredient mo-
metasone furoate (0.1%) was regarded to be similar for Mo-
metasone cream and the mometasone comparator. Using 
the psoriasis plaque test, a strong antipsoriatic effect com-
parable to that of the mometasone comparator was found 
for Mometasone cream after 12 days of occlusive treatment. 
A nearly identical reduction in the mean infiltrate thickness 
and similar mean AUC values were noted with both formula-
tions confirmed by clinical assessment data. The noninferior-
ity of Mometasone cream to its active comparator with re-
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atrophy  [4] and suppression of the hypothalamic pitu-
itary axis being of particular concern. Thus, pertinent 
research today mainly focuses on the improvement of the 
benefit/risk ratio of glucocorticoids  [2] . Apart from de-
signing new active congeners, a further issue is the devel-
opment of formulations with properties reflecting the 
current state of the skin  [5] and the differing expectations 
of the patients.
 The development of mometasone furoate, a (2) fu-
roate-17 ester with chlorine substituents at positions 9 and 
21  [3] , has been a result of efforts to separate the wanted 
from the unwanted effects of topically applied glucocorti-
coids. This corticoid combines high potency (classifica-
tion as a class III, i.e. high-strength steroid according to 
Braun-Falco et al.  [6] ) with low systemic availability after 
topical administration. The resulting low systemic toxic-
ity reflects an improved risk-benefit profile, compared to 
previous moderately potent topical glucocorticoids  [7, 8] . 
Due to its low percutaneous absorption, together with 
rapid hepatic biotransformation, topically applied mo-
metasone furoate does not show a significant effect on the 
hypothalamic pituitary axis  [3] . Furthermore, its atropho-
genic potential and risk of sensitization are considered low 
 [9] . Thus, the therapeutic effects clearly outweigh the un-
wanted effects; correspondingly, a therapeutic index of 2.0 
has been attributed to this glucocorticoid  [10] . Today, mo-
metasone furoate is established as a topical standard med-
ication in the management of patients with inflammatory 
skin disorders  [9] .
 Topical glucocorticoids are formulated in a variety of 
vehicles such as ointments, creams, lotions and gels  [11] . 
The efficacy of a glucocorticoid formulation is consider-
ably influenced by its vehicle  [12] . This also applies to 
mometasone furoate  [8] . In fact, the vehicle has a great 
influence on the agent’s penetration into the stratum cor-
neum and, consequently, on the local bioavailability and 
efficacy of the glucocorticoid  [11, 13–15] . A generic glu-
cocorticoid preparation is therefore not necessarily inter-
changeable with the respective originator product, unless 
its vehicle and, correspondingly, its topical availability 
are exactly the same. For approval, a generic topical prep-
aration has to undergo investigations to prove its bio-
equivalence with the originator product. Several test 
methods, among them the psoriasis plaque test (PPT) 
and the vasoconstrictor test, have been established as 
tools to compare the topical efficacy of glucocorticoid 
preparations  [16] .
 Ointments are often considered to be of a higher po-
tency than creams containing the same concentration of 
the active ingredient, probably due to their occlusive ef-
fect which may increase stratum corneum hydration and 
enhance drug transport  [11] . In contrast, Korting et al. 
 [17] could show earlier by means of a vasoconstrictor as-
say that a cream and a respective ointment containing the 
same concentration of mometasone furoate do not neces-
sarily differ in their activity. Generally, ointments are 
preferred in the treatment of infiltrated, lichenified le-
sions and creams for acute und subacute dermatoses, 
whereas lotions and gels are considered particularly suit-
able for scalp psoriasis  [11] . Patients themselves might 
particularly like light creams with respect to convenient 
daily application [publication in preparation]. This 
should be taken into account in dermatological therapy 
as patient compliance is crucial for treatment success  [18] .
 The purpose of the studies presented here was to de-
termine the noninferiority of a new light cream formula-
tion with the same content of the active ingredient mo-
metasone furoate of 0.1% as the originator, but with a 
higher water content of 33% compared to the originator 
cream with a water content of below 5% and a higher 
amount of lipids. The bioavailability of the formulations 
has been evaluated by means of a vasoconstrictor assay, 
and the antipsoriatic efficacy in a PPT. In both trials, 
safety issues have been observed concomitantly.
 A vasoconstrictor assay under standardized condi-
tions is well suited for assessing the in vivo bioavailabil-
ity of topical dermatological corticosteroids in humans. 
It is based on the property of corticosteroids to induce 
vasoconstriction represented by blanching of the skin 
 [19–21] . The vasoconstrictive strength is known to cor-
relate strongly with the clinical efficacy of topical gluco-
corticoids as determined in clinical treatment trials  [22] .
 Since its introduction by Dumas and Scholtz  [23]  in 
1972, the PPT is recognized as a suitable method for the 
assessment of antipsoriatic action. The clinical relevance 
of the test results has been demonstrated  [24] .
 Dermal tolerability of the new formulation was deter-
mined following repeated application of the drug during 
a 21-day treatment period.
 Materials and Methods 
All studies were performed by bioskin GmbH, Hamburg, Ger-
many, in accordance with the ‘Somerset West’ Declaration of Hel-
sinki (October 1996) as well as German regulations. The ICH 
guideline for Good Clinical Practice (January 1997) was ob-
served. The study protocol and other relevant documents were 
submitted to the Ethics Committee of the Hamburg Medical 
Council for review prior to the initiation of the study. Approval 
was granted for performance of the studies as outlined in the pro-
tocol. There were no amendments.
 Efficacy and Tolerability of Mometasone 
Cream 
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 Vasoconstriction Assay 
 Test Subjects and Medication 
 The aim of the study was to determine the bioavailability of 
topical mometasone cream formulations, each containing 0.1% 
mometasone furoate, in a vasoconstrictor assay in subjects with 
healthy skin. Between April and May 2008, 31 male and female 
(not pregnant) subjects with healthy skin aged 18 years or older 
were enrolled in this single-center, randomized, vehicle-con-
trolled, observer-blind study.
 A gender-specific subdivision into groups was not necessary 
as the topical bioavailability is equally detectable in men and 
women. Only ‘responders’ to glucocorticosteroids, i.e. people who 
had shown adequate vasoconstriction to a topical glucocortico-
steroid within the 2 weeks prior to the study, were eligible for this 
trial. The subjects were selected according to defined inclusion 
and exclusion criteria.  One person dropped out of the study. Data 
from 30 subjects were valid for analysis.
 The test product was a cream with 0.1% mometasone furoate, 
with a light texture and improved spreadability due to its water 
content of 33% (Monovo  cream, Almirall Hermal GmbH, Rein-
bek, Germany; referred to as Mometasone cream). The reference 
products used were a class II glucocorticoid preparation with 0.1% 
triamcinolone acetonide (Triamgalen  Creme, Galen, Kiel, Ger-
many; referred to as triamcinolone cream), a fatty cream with 
0.1% mometasone furoate (class III) (Ecural  Fettcreme, Schering 
Plough (Merck Sharp & Dohme Ltd), international trade name 
Elocon  ; referred to as mometasone comparator) and a cream 
with 0.05% of the class IV glucocorticoid clobetasol propionate 
(Dermoxin  Creme, GlaxoSmithKline plc., international trade 
name Dermovate  ; referred to as clobetasol cream). In addition, 
the active-ingredient-free vehicle to Mometasone cream was used 
as a negative control (for ingredients of the test product and refer-
ence products, see  table 1 ).
 An amount of approximately 50   l of each preparation was 
applied (as a single topical nonocclusive application) for 6 h  8 10 
min to test fields (2 cm 2 ) located on the volar surface of the fore-
arms of the test subjects. One control field on each arm remained 
untreated. Skin color in the treated and untreated test fields was 
measured using chromametry, and the degree of vasoconstriction 
was clinically assessed and compared. Chromametric measure-
ments and clinical assessments were performed at baseline and 1, 
2, 4, 6 and 18 h after the 6-hour treatment.
 Evaluation of Bioavailability and Safety 
 Blanching representing the vasoconstrictor properties of the 
respective test substance was evaluated as a primary variable by a 
chromametric measurement (redness value a * ) of skin redness us-
ing a Chroma-Meter CR 300 (Minolta, Ahrensburg, Germany). 
Measurements were performed by softly placing the measuring 
head upon the test field and triggering. One measurement series 
consisted of three individual measurements taken in every field. 
The respective values were entered into the study database.
 Clinical assessment as a secondary variable was determined by 
scoring. The degree of vasoconstriction in a treatment field com-
pared to the untreated control field on the same forearm was clin-
ically assessed by the investigator (independent observer) before 
the chromametry series, and scored as follows: 0 = no vasocon-
striction, 1 = mild vasoconstriction, 2 = moderate vasoconstric-
Table 1.  Ingredients of the test and reference products
Mometasone cream Vehicle to Mometasone 
cream
Mometasone
comparator
Clobetasol cream Triamcinolone cream
1 mg/g of mometasone 
furoate
– 1 mg/g of 
mometasone furoate
0.5 mg/ml of 
clobetasol-17-
propionate
1 mg/g of 
triamcinolone 
acetonide
water content 33% water content 33% water content <5% water content 30.8%* water content 72.2%*
Purified water, white soft 
paraffin (contains butylated 
hydroxytoluene as 
antioxidant), liquid 
paraffin, 
2-methylpentane-2,4-diol, 
emulsifying cetostearyl 
alcohol (type A, contains 
disodium/potassium 
hydrogen phosphate for pH 
adjustment), macrogol, 
cetostearyl ether cetyl 
alcohol, glycerol, anhydrous 
citric acid, sodium citrate, 
xanthan gum
Purified water, white soft 
paraffin (contains butylated 
hydroxytoluene as 
antioxidant), liquid paraffin, 
2-methylpentane-2,4-diol, 
emulsifying cetostearyl 
alcohol (type A, contains 
disodium/potassium 
hydrogen phosphate for pH 
adjustment), macrogol, 
cetostearyl ether cetyl 
alcohol, glycerol, anhydrous 
citric acid, sodium citrate, 
xanthan gum
White soft paraffin, 
hexylene glycol, 
aluminium starch, 
octenylsuccinate, 
propylene 
glycolstearate, 
stearyl alcohol, 
ceteareth-20, white 
beeswax, titanium 
dioxide, phosphoric 
acid, purified water
Chlorocresol, glyceryl 
monostearate, 
cetostearyl alcohol, 
Arlacel 165, beeswax 
substitute 6621, 
sodium citrate, citric 
acid monohydratete, 
propylene glycol, 
purified water
Phenoxyethanol 3.6 
mg,  decyloleate, 
cetylstearyl alcohol, 
cetomacrogol 1000, 
propylene glycol, 
dimeticon 20, citric 
acid waterfree, 
sodium hydrogen 
phosphate 2H2O, 
water
* Determined by Karl Fischer titration.
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tion, 3 = intense vasoconstriction. Safety was evaluated by medi-
cal history, screening, final clinical examination and the record-
ing of adverse events (AEs). Laboratory parameters were not 
controlled during the course of the study.
 Statistics 
 The primary efficacy variable consisted of the degree of red-
ness of the skin, measured as the area under the time curve (AUC) 
of the baseline-corrected, untreated control-site-corrected chro-
maticity (a-values). Clinical assessment scores for the degree of 
vasoconstriction were recorded as a secondary variable. The chro-
mametric a-value measurements were taken, and baseline adjust-
ments were made for each test field and assessment point. These 
baseline-corrected chromametric values were referred to as a * -
values. For each treatment group, the AUC was calculated for the 
respective a-values using the trapezoid rule. For the cardinally 
scaled a-values and the derived a * -values as well as for the AUC, 
descriptive statistics (valid number, mean, standard deviation, 
minimum and maximum) were carried out.
 Clinical assessment scores were descriptively evaluated and 
the scores were presented in frequency tables. Score sums were 
also calculated.
 The hierarchical approach was performed for the active study 
preparation and its corresponding vehicles. The overall signifi-
cance level of 5% could be kept with this ordered test procedure.
 Psoriasis Plaque Test 
 Test Subjects and Medication 
 The aim of the study was to determine the noninferiority of a 
topical mometasone formulation to a marketed comparator by 
evaluation of the antipsoriatic efficacy in a PPT. Between June and 
July 2008, 22 male and female (not pregnant) subjects with chron-
ic plaque-type psoriasis, aged 18–75 years, were enrolled in this 
phase II, single-center, randomized, controlled, observer-blind 
study. A gender-specific subdivision into groups was not neces-
sary as the antipsoriatic efficacy is equally detectable in men and 
in women. An up-to-date medical history was recorded and a 
physical examination performed during the 2 weeks before the 
study started. Patients with psoriasis guttata, psoriasis punctata, 
psoriasis erythrodermatica, psoriasis arthropathica and pustular 
psoriasis and those treated with antipsoriatics (except for salicyl-
ic acid in vaseline) in the 4 weeks preceding and/or during the 
study were excluded, as were those treated with any topical anti-
psoriatic (except for salicylic acid) in the 8 weeks preceding and/
or during the study. No patients dropped out. The data of all 22 
subjects were valid for the intention-to-treat (ITT) and per-pro-
tocol analyses.
 Medication 
 The test product used was Mometasone cream. The reference 
product was the mometasone comparator; the active-ingredient-
free vehicle to Mometasone cream served as a negative control. 
Three test fields (1.1 cm 2 ) in all were examined per subject, the 
treatments randomly assigned to the test fields in an observer-
blind manner, and the study preparations applied under Duhring 
chambers (diameter 12 mm inside and 14 mm outside) seated in 
holes punched in a hydrocolloid dressing (Varihesive  , Bristol-
Myers Squibb, Munich, Germany). The test fields were treated 
occlusively with either Mometasone cream (200-  l formulation/
test field representing 0.2 mg active ingredient/day), active-ingre-
dient-free vehicle to Mometasone cream (200-  l formulation/test 
field representing 0.0 mg active ingredient/day), or the mometa-
sone comparator (200-  l formulation/test field representing 0.2 
mg active ingredient/day) over a study period of 12 days (10 treat-
ments). The total overall dosage of active ingredient was approxi-
mately 4.0 mg mometasone furoate for every subject. On study 
days 2–6 and 8–11, the occluding chambers were removed and the 
treatments renewed once daily.
 Evaluation of Efficacy and Safety 
 The hydrocolloid dressing was removed on study days 4, 8 and 
12, and sonography and clinical assessment were performed after 
removing preparation residues. Sonographic measurements were 
performed using a 20-MHz high-frequency sonograph (DUB-
USB, Taberna pro Medicum, Lueneburg, Germany). Depending 
on the echo patterns, components of the epidermis, dermis and 
subcutis were addressed to allow for exact measurement of the 
skin thickness. The inflammatory psoriatic infiltrate was seen as 
a clearly definable echo lucent band below the entrance echo. The 
thickness of the echo lucent psoriatic band was determined and 
documented. On study days 4, 8, and 12, clinical assessment of the 
test fields was performed using a 5-point score (–1 = worsened,
0 = unchanged (no effect), 1 = slight improvement, 2 = clear im-
provement but not completely healed, 3 = completely healed). A 
comparison was made with the untreated plaque beneath the hy-
drocolloid dressing. Clinically apparent differences in erythema 
and infiltration contributed to this global assessment. On study 
days 1 and 12, photo documentation and clinical examination 
were performed. Safety was evaluated by screening, final clinical 
examinations and the recording of AEs.
 Statistics 
The primary efficacy variable was the AUC calculated from 
the infiltrate thickness differences to baseline, established for the 
3 measuring points following the baseline visit, separately. Sec-
ondary variables were the infiltrate thickness (sonography), and 
the clinical assessment (scores), assessed or measured at the vari-
ous test points. The aim of this study was to prove the noninferi-
ority of Mometasone cream to the mometasone comparator using 
a noninferiority margin   = 250 with respect to the AUC of 
change to baseline in infiltrate thickness, with a lower AUC being 
superior. The secondary endpoint of superiority of Mometasone 
cream to the active-ingredient-free vehicle, with respect to the 
AUC of change to baseline in infiltrate thickness, was also as-
sessed by the confidence interval (CI) method. The additional 
secondary endpoints, i.e. changes to baseline in, and sonographic 
measurements of infiltrate thickness, clinical scores for the as-
sessment of efficacy and adverse effects were evaluated by means 
of descriptive statistics.
 Dermal Tolerability Test 
 Test Subjects and Medication 
 The study also aimed to determine the dermal tolerability of 
Mometasone cream on intact skin following repeated application 
over a 21-day treatment period. Between May and June 2008, 33 
male and female (not pregnant) volunteers – aged 18 or older – 
with healthy skin in the area of the test fields (on which reddening 
could easily be recognized) were enrolled in this single-center, 
randomized, controlled study which was double-blind for the 
study preparations. One subject dropped out. Data from all 33 
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subjects were valid for safety and ITT analyses. Data from 31 sub-
jects were valid for per-protocol analysis; these subjects received 
all treatments.
 Medication 
 The test product used was Mometasone cream as described 
above. The reference products were the active-ingredient-free ve-
hicle to Mometasone cream, purified water as a negative control 
and 0.3% sodium dodecyl sulfate in water (SDS) as a positive con-
trol. Altogether, 4 test fields on intact skin on the back were ex-
amined. The test fields were treated occlusively, using special test 
chambers once daily (approx. 100   l/test field of 2.5 cm 2 ) with the 
study preparations and controls during a 21-day treatment period 
(18 treatments).
 Evaluation of Tolerability and Safety 
 Clinical assessment of the test fields was performed on study 
days 2–6, 8–13, 15–20 and on day 22. Dermal reactions were clin-
ically assessed using a score prior to renewed application on study 
days 2–21 and on day 22. Nonspecific local irritating reactions to 
the study preparations were evaluated. Safety was evaluated by 
screening, final clinical examinations and the recording of AEs.
 Statistics 
 To summarize the tolerability, a cumulative irritation index 
was calculated based on the sum of the cumulative irritation 
scores for all subjects on day 22. Tolerability data were analyzed 
by treatment and day using descriptive statistical methods. Dif-
ferences between the treatments were tested by the exact Wilcox-
on signed-rank test at level   = 0.05. As this was an exploratory 
study, no adjustment for multiple testing was performed and the 
obtained p values were only interpreted descriptively.
 Results 
 Vasoconstriction Assay 
 The blanching effect observed with Mometasone cream 
was comparably pronounced in comparison to that seen 
with the mometasone comparator and clobetasol cream, 
and superior to that of triamcinolone cream. The active-
ingredient-free vehicle to Mometasone cream had no rel-
evant blanching effect. The chromametric measurements 
demonstrated a clear reduction in skin redness for Mo-
metasone cream and the reference products mometasone 
comparator and clobetasol cream. Similar mean AUC val-
ues were noted for Mometasone cream, the mometasone 
comparator and clobetasol cream (45.57, 46.95 and 49.55, 
respectively). A lower mean AUC value was noted for tri-
amcinolone cream (30.08). No-to-minimal blanching was 
noted in the fields treated with the vehicle cream (mean 
AUC = 0.11) ( fig.  1 ). The maximum mean baseline-cor-
rected, untreated control-site-corrected a-value of Mo-
metasone cream 18 h after the 6-hour treatment was 3.62. 
A similar reduction in skin redness was observed for the 
mometasone comparator and clobetasol cream (mean 
baseline-corrected, untreated control-site-corrected a-val-
ues = a * -values; 3.80 and 3.62, respectively). A lower max-
imum mean a-value (baseline-corrected, untreated con-
trol-site-corrected) was noted for triamcinolone cream 
(2.35), and a value just above zero indicated that the vehicle 
to Mometasone cream had no blanching effect.
 In the statistical analyses, the lower 95% CI limits of 
the AUC of Mometasone cream, triamcinolone cream, 
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the mometasone comparator and clobetasol cream were 
greater than zero. Therefore, it could be concluded that 
these 4 preparations were effective with respect to blanch-
ing. In the hierarchical testing, it was shown that Mo-
metasone cream was more effective than the respective 
vehicle (not shown). The noninferiority of Mometasone 
cream to the comparators of lower strength (triamcino-
lone cream) and similar strength (mometasone compara-
tor) could be demonstrated in all 3 cases considering a 
20% margin. The noninferiority of Mometasone cream 
to the higher-strength comparator clobetasol cream 
could not be confirmed.
 The clinical assessment reflected the results of the 
chromametric investigation ( table  2 ). Moderate-to-in-
tense vasoconstriction was noted in the test fields treated 
with Mometasone cream, mometasone comparator and 
clobetasol cream in nearly all subjects, and in the test 
fields treated with triamcinolone cream in more than half 
of the subjects. The vasoconstriction achieved with Mo-
metasone cream was comparable to the effect seen for the 
mometasone comparator and clobetasol cream and supe-
rior to the effect seen for triamcinolone cream ( table 2 ). 
In the test fields treated with the vehicle cream, the ma-
jority of the subjects showed no vasoconstriction. In this 
study, no AEs occurred and no observations related to 
safety were recorded. The final physical examination at 
the end of the study did not show abnormal findings in 
any of the subjects.
 Psoriasis Plaque Test 
 Mometasone cream demonstrated a strong positive ef-
fect in the treatment of psoriasis in the PPT. The antipso-
riatic effect of Mometasone cream was comparable to the 
effect seen for the mometasone comparator on the basis 
of the sonographic measurements ( fig. 2 ). In the inferen-
tial analyses of the AUC of change to baseline in infiltrate 
thickness, the noninferiority of Mometasone cream to 
the mometasone comparator could be shown ( table  3 ). 
The upper CI limit (68.8) was lower than the inferiority 
margin   = 250. The nearly identical mean percentaged 
reductions in infiltrate thickness after 12 days of treat-
ment with Mometasone cream and the mometasone 
comparator (–70.16 and –70.53%, respectively) as well as 
the similar mean AUC values (–2,037.0 and –1,981.3, re-
spectively) underlined the comparability of both formu-
lations. As expected, no relevant antipsoriatic effect was 
noted for the active-ingredient-free vehicle. After 12 days 
of treatment with the vehicle, a percent reduction of 
1.59% was noted and the AUC was clearly higher than for 
the 2 active formulations (–47.1). The superiority of Mo-
metasone cream (0.1% mometasone furoate) to the vehi-
cle, with respect to the AUC of change to baseline in in-
filtrate thickness, was proven since the upper CI of the 
difference of these 2 formulations (–1,719.8) was below 0 
( table 3 ).
 The global clinical assessment supported the results of 
the sonographic measurements. Comparable clinical im-
provement was seen for both Mometasone cream and the 
Table 2.  Vasoconstriction assay: clinical assessment 18 h after the 
6-hour treatment (n = 30) 
1 h 2 h 4 h 6 h 18 h Pooled
Mometasone cream
Median score 2 2 2 3 1
Sum score 63 65 72 76 25 301
Vehicle to Mometasone cream
Median score 0 0 0 0 0
Sum score 3 2 1 1 0 7
Triamcinolone cream
Median score 1 1 2 2 0.5
Sum score 30 35 44 51 17 177
Mometasone comparator 
Median score 2 2 3 3 1
Sum score 61 71 79 80 28 319
Clobetasol cream
Median score 2 2 2.5 3 1
Sum score 50 62 69 75 34 290
 Median score and sum score: 0 = no vasoconstriction, 1 = mild 
vasoconstriction, 2 = moderate vasoconstriction, 3 = intense va-
soconstriction. 
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mometasone comparator, whereas no clinical improve-
ment was seen with the active-ingredient-free vehicle. 
The course of the clinical assessment scores was nearly 
identical for Mometasone cream and the mometasone 
comparator (not shown). After 12 days of treatment with 
Mometasone cream and the mometasone comparator, a 
distinct improvement but not complete healing (score = 
2) was noted in most of the subjects (16 of 22, each). A 
slight improvement (score = 1) was noted in 5 subjects 
and ‘completely healed’ (score = 3) in 1 subject for both 
treatments, respectively. The median was 2 for both for-
mulations on study day 12. In nearly all subjects after 12 
days of treatment with the active-ingredient-free vehi-
cle, no effect (score = 0) was seen. Worsening (score = –1) 
was not noted in any of the subjects.
 Only 1, nonserious AE (diarrhea) was reported in this 
study. The final physical examination did not show ab-
normal findings in any of the subjects. The dermal toler-
ability was good and comparable for all study prepara-
tions – even under the occlusive conditions in this study.
 Dermal Tolerability Test 
 Under the study conditions with occlusive topical ap-
plication once daily for 21 days, Mometasone cream was 
moderately tolerated. Of the volunteers treated with Mo-
metasone cream, 56.3% showed erythematous score 1 re-
actions, compared to 37.5% of those treated with the ve-
hicle (not shown). In both groups treated with Mometa-
sone cream or with the vehicle, 21.9% of the subjects 
showed erythematous score 2 reactions. At the end of the 
study (day 22), 87.6% of the subjects treated with Mo-
metasone cream and 96.9% of the subjects treated with 
the vehicle did not show signs of clinically relevant skin 
irritation (score 0 and 1 reactions). The total score sum 
for days 2–22 was 337 of a possible maximum of 2,316 
expressed as the cumulative irritation index: 337/2,316 
(14.6%) for Mometasone cream. The cumulative irrita-
tion index for the vehicle for days 2–22 was 228/2,316 
(9.8%), for the negative control (purified water) 4/2,316 
(0.2%) and for the positive control (0.3% SDS) 1,284/2,316 
(55.4%).
 The cumulative irritation score of Mometasone cream 
for day 22 was clearly higher compared to the corre-
sponding vehicle (p = 0.0289) and the negative control 
(p  ! 0.0001), but lower compared to the positive control 
(p  ! 0.0001) (not shown). The vehicle cream had a cumu-
lative irritation score lower than the positive control and 
higher than the negative control (p  ! 0.0001 each). Alto-
gether 5 nonserious AEs in 4 subjects were reported. One, 
gastroenteritis, was classified as moderate and the subject 
discontinued the study; all others, headache, acute hay 
fever, injury of upper lip and nausea, were classified as 
mild. In 4 AEs, the relationship to study medication was 
considered to be unlikely, and in 1 to not be related. There 
were no other relevant observations related to safety.
 Discussion 
 For five decades, glucocorticoids have been used as 
suitable medications for the treatment of skin disorders 
associated with inflammatory processes  [1–3] . As the 
long-term use of older glucocorticoids was often limited 
by side effects such as skin atrophy  [4] , new steroids were 
developed in the late 1980s with the object of increasing 
efficacy and reducing the incidence of adverse effects. 
Mometasone furoate is one of these new derivatives  [25] . 
The agent offers a high local concentration at the site of 
Table 3.  PPT: inferential analyses of AUC of change to baseline in infiltrate thickness (m) for the ITT population
Treatment T Treatment R Mean AUC of change
to baseline in infiltrate
thickness (T)
Mean AUC of change
to baseline in infiltrate
thickness (R)
Mean AUC
differences
(T – R)
95% Two-sided3 CI
of T – R
ITT population
Mometasone cream Mometasone comparator –2,037.0 –1,981.3 –55.7 –180.1/–68.81
Mometasone cream vehicle to Mometasone cream –2,037.0 –47.1 –1,989.9 –2,260.0/–1,719.82
R = Reference product; T = test product. 
1 If the upper CI is lower than the noninferiority margin  = 250, then the noninferiority of Mometasone cream to the mometa-
sone comparator is proven.
2 If the upper CI is below 0, then the superiority of Mometasone cream to active-ingredient-free vehicle is proven.
3 The upper 95% two-sided CI of T – R is equal to the 97.5% one-sided CI of T – R.
 Korting  /Schöllmann  /Willers  /
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application, the extended persistence of which is associ-
ated with a low absorption rate into the systemic circula-
tion  [8] . Due to its potency (class III steroid), its low per-
cutaneous absorption, low systemic toxicity and low at-
rophogenic potential/risk of sensitization  [7, 9, 26, 27] and 
thus a favorable benefit/risk ratio  [7, 8] , topically applied 
mometasone furoate has emerged as a standard medica-
tion for the treatment of inflammatory skin disorders  [9, 
28, 29] .
 However, not only the active pharmaceutical ingredi-
ent itself but various additional factors such as the base, 
penetration enhancers and other additives influence the 
activity of a topical formulation  [8, 12–15, 25, 30] , show-
ing that the efficacy of a glucocorticoid formulation is 
dependent on the chosen vehicle. Kulhalli et al.  [8] dem-
onstrated this for mometasone furoate, whereas Korting 
et al.  [17] found that a cream and an ointment which con-
tain the same concentration of mometasone furoate do 
not differ in their activity.
 Regardless of the role of the vehicle for the efficacy of 
a glucocorticoid formulation in general, and of mometa-
sone furoate formulation in particular, patient compli-
ance plays an additional and crucial role for glucocorti-
coid efficiency  [18] – an aspect that should increasingly 
be taken into consideration in the treatment of skin dis-
eases. As patients with inflammatory skin disease may 
prefer light creams to fatty creams with respect to conve-
nient, daily application [publication in preparation], the 
introduction of a light cream should be a valuable addi-
tion to our therapeutic armamentarium.
 In the studies presented here, we could demonstrate 
the topical bioavailability, antipsoriatic efficacy and tol-
erability of Mometasone cream, a new light cream (O/W 
60/40 emulsion) with mometasone furoate 0.1% with a 
water content of 33%. In the first study we could demon-
strate a strong blanching effect of Mometasone cream us-
ing the vasoconstrictor assay ( tables 2 ,  3 ). The effect was 
comparable to that of the mometasone comparator, a fat-
ty cream with mometasone furoate 0.1% with a water 
content  ! 5%, and stronger than the effect seen for triam-
cinolone cream ( fig. 1 ). The topical bioavailability of all 
active formulations was shown by chromametric mea-
surement and clinical assessment. As expected, no rele-
vant blanching effect was seen for the active-ingredient-
free vehicle to Mometasone cream. As expected, the bio-
availability of the active ingredient mometasone furoate 
(0.1%) was similar for Mometasone cream and the mo-
metasone comparator.
 This result could also be supported by means of a PPT, 
a suitable method for the assessment of antipsoriatic ac-
tion  [23] . In this assay, a strong antipsoriatic effect com-
parable to that of the mometasone comparator was found 
for Mometasone cream. A relevant and nearly identical 
reduction in the mean infiltrate thickness and similar 
mean AUC values was noted with both 0.1% mometasone 
furoate-containing formulations ( fig.  2 ) – a result con-
firmed by the clinical assessment data. A specific analysis 
of the data established the noninferiority of Mometasone 
cream to the mometasone comparator with respect to the 
AUC of change to baseline in infiltrate thickness. The fair 
tolerability of Mometasone cream, as observed in both 
tests, could also be confirmed in the dermal tolerability 
assay presented in this paper. Under the conditions of the 
dermal tolerability study, both Mometasone cream and 
its active-ingredient-free vehicle demonstrated a mild-to-
moderate irritant potential.
 In summary, both preparations – Mometasone cream 
and the mometasone comparator – showed a favorable 
benefit/risk ratio and both could, in particular, be con-
sidered for the treatment of acute und subacute dermato-
ses where creams are generally recommended  [11] . How-
ever, in comparison to the mometasone comparator, 
 Mometasone cream combines a high potency and good 
tolerability with the properties of a light cream, i.e. easy 
and convenient application, characteristics which are ap-
preciated by patients with inflammatory skin diseases.
 Conclusion 
 Mometasone cream, a new light cream (O/W 60/40 
emulsion) with mometasone furoate 0.1%, displays a sim-
ilar efficacy and tolerability to the mometasone compar-
ator, but also the properties of a light cream. This makes 
this topical medication a viable alternative when it comes 
to the treatment of acute inflammatory skin diseases.
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